SuperworthBiomarin Pharmaceutical free cash flow BMRN
Cash from operations less capital spending, by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jun 30, 2026
- $738.2M
- Latest quarter, Q2 FY26
- $139.3M
- −17% on a year earlier
- Fiscal year 2025
- $725M
- +49% on the year before
Biomarin Pharmaceutical's free cash flow was $738.2M over the twelve months to Jun 30, 2026, up 6% on a year earlier.
In its latest quarter, Q2 FY26, it was $139.3M, down 17% on the same quarter a year before.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2025 | $725M | +49% |
| FY2024 | $487.4M | +679% |
| FY2023 | $62.6M | +14% |
| FY2022 | $54.9M | −74% |
| FY2021 | $209M | n/a |
| FY2020 | −$28.9M | n/a |
| FY2019 | −$96.8M | n/a |
| FY2018 | −$124.4M | n/a |
| FY2017 | −$208M | n/a |
| FY2016 | −$376.2M | n/a |
| FY2015 | −$447.2M | n/a |
| FY2014 | −$189M | n/a |
| FY2013 | −$124.8M | n/a |
| FY2012 | −$27M | n/a |
| FY2011 | −$54.5M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $139.3M | −17% | $738.2M | |
| Q1 FY26 | $199.7M | +27% | $767.1M | |
| Q4 FY25 | $58.9M | −65% | $725M | |
| Q3 FY25 | $340.2M | +68% | $832.1M | |
| Q2 FY25 | $168.2M | +73% | $694.9M | |
| Q1 FY25 | $157.6M | +655% | $624.2M | |
| Q4 FY24 | $166.1M | n/a | $487.4M | |
| Q3 FY24 | $203M | +78% | $319.9M | |
| Q2 FY24 | $97.4M | +101% | $230.8M | |
| Q1 FY24 | $20.9M | n/a | $181.8M | |
| Q4 FY23 | −$1.4M | n/a | $62.6M | |
| Q3 FY23 | $113.9M | −12% | $35.1M |
Against its peers
Companies in Drug Manufacturers - General nearest Biomarin Pharmaceutical's size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| BMRNBiomarin Pharmaceutical | 6.8% |
| CORTCorcept Therapeutics | 1.2% |
| PTGXProtagonist Therapeutics | 1.5% |
| JAZZJazz Pharmaceuticals | 11.5% |
| TGTXTG Therapeutics | 0.2% |
| ALKSAlkermes plc. | 3.0% |
| AMRXAmneal Pharmaceuticals | 2.0% |
| LGNDLigand Pharmaceuticals | 2.2% |
| KNSAKiniksa Pharmaceuticals International | 3.1% |
| INDVIndivior Pharmaceuticals | −2.7% |
| ARQTArcutis Biotherapeutics | 1.0% |
| Peer median | 1.7% |
Where Biomarin Pharmaceutical ranks
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Biomarin Pharmaceutical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.